Author

H. U. Kaniskan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:deep learning· 2 Approach:experimental assay· 2 Organism:virus· 2 Approach:diffusion model· 1 Assay:protein structure· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

J. Jin· 4 shared F. Li· 3 shared I. Chau· 3 shared M. Vedadi· 3 shared K.-S. Park· 2 shared M. Schapira· 2 shared A. Aspuru-Guzik· 1 shared A. Gastia-Sastre· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

J. Jin

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Drug Discovery in Low Data Regimes: Leveraging a Computational Pipeline for the Discovery of Novel SARS-CoV-2 Nsp14-MTase Inhibitors

A. Nigam, M. F. D. Hurley, F. Li, E. Konkolova, M. Klima, J. Trylcova, R. Pollice, S. S. Cınaroglu, R. Levin-Konigsberg, J. Handjaya, M. Schapira, I. Chau, S. Perveen, H.-L. Ng, H. U. Kaniskan, , A. Aspuru-Guzik

This paper introduces a computational pipeline for identifying SARS-CoV-2 nsp14 inhibitors using virtual screening, identifying seven candidates including NSC620333 and SS148, with experimental validation of binding affinity and structural insights.

bioRxiv · Oct 3, 2023 · PreprintBiochemistry

Structure-based discovery of inhibitors of the SARS-CoV-2 Nsp14 N7-methyltransferase

I. Singh, F. Li, E. Fink, I. Chau, A. Li, A. Rodriguez-Hernandez, I. Glenn, F. J. Zapatero-Belinchon, M. Rodriguez, K. Devkota, Z. Deng, K. White, X. Wan, N. A. Tolmachova, Y. S. Moroz, , B. K. Shoichet

The paper identifies multiple inhibitors of SARS-CoV-2 Nsp14 N7-methyltransferase using docking strategies, with some showing sub-10 M potency and selectivity.

bioRxiv · Jan 12, 2023 · PreprintBiophysics

Targeted degradation of PRC1 components, BMI1 and RING1B, via a novel protein complex degrader strategy

K.-S. Park, L. Qin, M. Kabir, K. Luo, B. Dale, Y. Zhong, A. Kim, G. Wang, H. U. Kaniskan, J. Jin

This paper introduces MS147, a novel degrader of PRC1 components BMI1 and RING1B, which selectively degrades these proteins and inhibits cancer cell proliferation.

bioRxiv · Nov 19, 2022Biochemistry

A First-in-class, Highly Selective and Cell-active AllostericInhibitor of Protein Arginine Methyltransferase 6 (PRMT6)

Y. Shen, F. Li, M. Szewczyk, L. Halabelian, I. Chau, M. S. Eram, C. Dela Sena, K.-S. Park, F. Meng, H. Chen, H. Zeng, D. McLeod, C. A. Zepeda-Velazquez, R. M. Campbell, M. M. Mader, , J. Jin

This paper reports the discovery of a first-in-class, highly selective allosteric inhibitor of PRMT6, SGC6870, with potent activity and selectivity in vitro and in cells.

bioRxiv · Dec 4, 2020 · PreprintBiochemistry